Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
The U.S. Food and Drug Administration has granted priority review to Merck‘s application requesting the approval of Keytruda (pembrolizumab) in combination ... Read more
Immune checkpoint inhibitor Bavencio (avelumab) shows durable clinical activity and long-term disease control among heavily pretreated malignant mesothelioma patients, according to ... Read more
The U.S. Food and Drug Administration has expanded Alimta‘s (pemetrexed) label to include a combination with Keytruda (pembrolizumab) and platinum chemotherapy for the initial treatment ... Read more
The European Commission has approved a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) for the initial treatment of advanced renal ... Read more
A combination of Opdivo (nivolumab) and standard Vidaza (azacitidine) chemotherapy reduced the tumor burden in one-third of acute myeloid leukemia (AML) patients ... Read more
Patients with human immunodeficiency virus (HIV) may safely receive immune checkpoint inhibitors as a cancer treatment, as long as they continue ... Read more
A combination of Opdivo (nivoumab) and Yervoy (ipilimumab) significantly delayed the need for a subsequent treatment in patients with advanced or ... Read more
The immune checkpoint inhibitor Keytruda (pembrolizumab) completely eliminated tumors in almost 40% of a group of bladder cancer patients in an ... Read more
